- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00254241
Safety and Efficacy of Seroquel in First Episode Schizophrenia
June 9, 2009 updated by: AstraZeneca
To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode schizophrenia
Study Overview
Study Type
Interventional
Enrollment
80
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-35 years Meet ICD-10 criteria for schizophrenia No abnormaility on clinical examination No previous episode of psychosis No previous antipsychotics of any kind in last 3 months
Exclusion Criteria:
- Have received a course of antipsychotics drug treatment prior to entry which may introduce risk factors or interfere with study procedures Have received anticholinergics within 10 days of baseline aseessment Have received mood stabilizers or anti depressants within 2 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The proportion of patients developing clinically significant EPS at any point between baseline (day 1) and final assessment
|
Secondary Outcome Measures
Outcome Measure |
---|
CGI severity of illness
|
CGI global improvement
|
PANSS total score and subscales)
|
Abnormal Involuntary Movement Scale (AIMS)
|
Dose of anti cholinergic medication
|
Serum prolactin levels
|
Proportion of patients discontinuing treatment due to reasons of lack of efficacy or adverse effects
|
Proportion of patients experiencing relapse.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: AstraZeneca Seroquel Medical Science Director, MD, AstraZenenca
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Study Completion (Actual)
June 1, 2006
Study Registration Dates
First Submitted
November 14, 2005
First Submitted That Met QC Criteria
November 14, 2005
First Posted (Estimate)
November 16, 2005
Study Record Updates
Last Update Posted (Estimate)
June 11, 2009
Last Update Submitted That Met QC Criteria
June 9, 2009
Last Verified
June 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Quetiapine Fumarate
- Risperidone
Other Study ID Numbers
- BU-5077-0011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Seroquel and Risperidone
-
Shanghai Mental Health CenterCompleted
-
AstraZenecaCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
University of Texas Southwestern Medical CenterStanley Medical Research Institute; University of North Texas Health Science...CompletedBipolar Disorder | Cocaine Dependence | Methamphetamine DependenceUnited States
-
AstraZenecaCompletedSchizophreniaItaly, Germany, Austria, Spain, Denmark
-
University of British ColumbiaBristol-Myers SquibbCompletedPsychotic Disorders | Bipolar Disorder | Metabolic Syndrome XCanada
-
AstraZenecaCompletedMajor Depressive DisorderBelgium
-
Rovi Pharmaceuticals LaboratoriesCompletedAcute SchizophreniaUnited States, Ukraine
-
Indiana University School of MedicineAstraZenecaCompleted
-
BC Women's Hospital & Health CentreCompletedPostpartum DepressionCanada